These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15663888)

  • 1. Development of novel therapies for Huntington's disease: hope and challenge.
    Qin ZH; Wang J; Gu ZL
    Acta Pharmacol Sin; 2005 Feb; 26(2):129-42. PubMed ID: 15663888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.
    Hersch SM
    Curr Opin Neurol; 2003 Aug; 16(4):501-6. PubMed ID: 12869810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies for Huntington's disease based on a molecular understanding of the disorder.
    Haque NS; Borghesani P; Isacson O
    Mol Med Today; 1997 Apr; 3(4):175-83. PubMed ID: 9134531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
    Bates GP; Hockly E
    Curr Opin Neurol; 2003 Aug; 16(4):465-70. PubMed ID: 12869804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's disease: an update of therapeutic strategies.
    Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
    Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine retards disease onset and progression in Huntingtin mutant mice.
    Duan W; Guo Z; Jiang H; Ladenheim B; Xu X; Cadet JL; Mattson MP
    Ann Neurol; 2004 Apr; 55(4):590-4. PubMed ID: 15048901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntington's disease: From molecular basis to therapeutic advances.
    Krobitsch S; Kazantsev AG
    Int J Biochem Cell Biol; 2011 Jan; 43(1):20-4. PubMed ID: 21056115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Huntington's disease: new hope for therapeutics.
    McMurray CT
    Trends Neurosci; 2001 Nov; 24(11 Suppl):S32-8. PubMed ID: 11881743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental models of HD and reflection on therapeutic strategies.
    Kim J; Bordiuk OL; Ferrante RJ
    Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Huntington's disease.
    Berman SB; Greenamyre JT
    Curr Neurol Neurosci Rep; 2006 Jul; 6(4):281-6. PubMed ID: 16822347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential drugs and methods for preventing or delaying the progression of Huntington's disease.
    Sari Y
    Recent Pat CNS Drug Discov; 2011 May; 6(2):80-90. PubMed ID: 21585328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's disease.
    MacDonald ME; Gines S; Gusella JF; Wheeler VC
    Neuromolecular Med; 2003; 4(1-2):7-20. PubMed ID: 14528049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the treatment studies in Huntington's disease since 1990.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hope for Huntington's from an old antibiotic.
    Ashraf H
    Drug Discov Today; 2005 Dec; 10(23-24):1582-3. PubMed ID: 16376812
    [No Abstract]   [Full Text] [Related]  

  • 16. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntington's disease: progress toward effective disease-modifying treatments and a cure.
    Johnson CD; Davidson BL
    Hum Mol Genet; 2010 Apr; 19(R1):R98-R102. PubMed ID: 20421366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.
    Skogen M; Roth J; Yerkes S; Parekh-Olmedo H; Kmiec E
    BMC Neurosci; 2006 Oct; 7():65. PubMed ID: 17014717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.